Drug intelligence / Profile preview

JW0108 + C2407

Development stage: Unknown
Lead developer: JW Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

JW0108 + C2407 is an investigational **combination therapy** being evaluated for the treatment of **dyslipidemia**. This regimen involves the **co-administration of two distinct agents, JW0108 and C2407**, in a fixed combination. The precise mechanism of action for each agent remains unspecified in the publicly available information, but the combination is being tested in a Phase 3, randomized, double-blind, parallel-group clinical trial. The development is led by JW Pharmaceutical, a company based in South Korea, with the aim to improve lipid profiles in patients with dyslipidemia[1][3].

Beyond the preview

Go deeper on JW0108 + C2407.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JW0108 + C2407.

Explore the full profile